Understanding the supply chain needs of your cell and gene therapy
A record number of new cell and gene therapies (CGTs) were approved in 2021[1], and there is a spike in commercializations on the horizon.
However, bringing a CGT to market is uniquely complex, particularly when it comes to creating the robust supply chains needed to deliver these time- and temperature-critical treatments safely.
In our roundtable with The Medicine Maker, Andrea Zobel of World Courier joined Bill Shingleton from Cytiva, Michael Terhoeven from Miltenyi Biomedicine and Phil Morton from Albumedix to explore the complexities of CGT commercialization.
Scrip Pharma Intelligence report
Building successful cell and gene therapy supply chains
This report summarizes the key takeaways from a recent round table with a panel of experts representing early stage biotech, pharmaceutical, supply chain management and logistics companies.
- Orchestrating cell and gene therapies requires bespoke solutions in terms of storage, transportation, timelines, temperature control, and servicer flexibility
- In these incredibly complex supply chains, forming and orchestrating partnerships is a necessity
- In order for logistics vendors to form partnerships with cell and gene therapy manufacturers it is important to understand each company's unique requirements
- Scalability of logistics solutions is also an important consideration
White paper
Setup a robust and scalable supply chain for cell and gene therapies
Written in partnership with Arvato, this white paper how to build a robust cryogenic logistics platform for allogeneic therapies that can scale up and out to support global commercialization goals.
Emerging cell and gene therapies, complex logistics eco-systems, and the need for greater industry collaboration
World Courier insights podcast
